The two faces of serotonin in bone biology by Ducy, Patricia & Karsenty, Gerard
The Rockefeller University Press    $30.00
J. Cell Biol. Vol. 191 No. 1  7–13
www.jcb.org/cgi/doi/10.1083/jcb.201006123 JCB 
JCB: Review
Introduction
The vertebrate skeleton, despite its unvarying appearance, is 
a remarkably dynamic organ. As a matter of fact, among all 
the organs of the body it is the only one that constantly self- 
destructs and rebuilds itself throughout life by a process called 
bone remodeling. During bone remodeling, two specialized cell 
types, osteoblasts and osteoclasts, lay down and destroy (resorb),   
respectively, a dense extracellular matrix that subsequently be-
comes mineralized. It is this succession of destruction and re-
construction that allows bones to grow, to repair microfractures, 
and to adapt to the structural needs of the body.
Given these unique properties, it is no surprise that bone 
must  have  developed  a  very  specific  process  of  remodeling 
compared with other, soft, tissues. Indeed, its rigid mineralized 
structure must use unique mechanisms for growth and for the 
adjustment to physiological needs and constraints. To modify 
shape, for a rigid structure like bone, it is far more effective to 
break the outdated form and to generate a new one. However, 
with this particular mode of overhauling comes a particular 
constraint: the two arms of bone remodeling, resorption and 
formation, need to be constantly balanced so that the equilib-
rium between them is never disrupted. It is for this reason that 
a wide variety of means exist to regulate osteoblast and osteo-
clast biology. Some are local like the rigorous control osteo-
blasts exert on the differentiation and function of osteoclasts 
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via their secretion of multiple cytokines; others are hormonal, 
such as the regulation of bone mass accrual by parathyroid hor-
mone (PTH), estrogen, and leptin; or even neuronal, such as the 
sympathetic control of bone formation (Wagner and Karsenty, 
2001; Teitelbaum and Ross, 2003; Karsenty et al., 2009). The 
discovery that serotonin plays a major role in controlling bone 
remodeling via two distinct, not just independent but also op-
posite, pathways adds another layer of complexity to this aspect 
of skeleton biology. Remarkably, it also reveals a promising 
therapeutic perspective to treat bone loss disorders such as   
osteoporosis, one of the most common degenerative diseases   
of the Western hemisphere.
The two identities of serotonin
Serotonin (5-hydroxytryptophan [5-HT]) was identified in 1948 
as a molecule present in serum (sero) and able to induce vaso-
constriction (tonin; Rapport et al., 1948a,b). Although serotonin 
regulates cardiovascular function (Kaumann and Levy, 2006), 
this name turned out to be misleading because serotonin roles 
are far broader than this. For instance, depending on its site of 
synthesis, serotonin affects physiological processes as different 
as primary hemostasis, anxiety, and bowel movement (Gingrich 
and Hen, 2001; Gershon and Tack, 2007; Berger et al., 2009). 
Surprisingly, most serotonin (95%) is produced in the periph-
ery, whereas only a minor fraction is synthesized in the brain, 
where it obtained its claim to fame. Indeed, in the last five de-
cades, serotonin’s function as a neurotransmitter has attracted   
the most attention from biologists as well as physicians (Gingrich 
and Hen, 2001). Shortly after its identification in brain extracts 
in 1953, the psychotropic role of serotonin began to surface, 
first through studies using serotonin analogues and lysergic acid   
diethylamide (LSD), a demonstrated serotonin antagonist on 
smooth muscle (Sjoerdsma and Palfreyman, 1990). Clinical stud-
ies then showed that tryptophan, the precursor of serotonin bio-
synthesis, had antidepressant properties and that depressed and 
manic patients had decreased concentrations of 5-hydroxy- 
indoleacetic acid (5-HIAA), the breakdown product of sero-
tonin, in their cerebrospinal fluid (Coppen et al., 1963, 1972; 
Ashcroft et al., 1966). These studies launched the highly suc-
cessful career of serotonin as a regulator of mood and behavior, 
and paved the way to a large body of work establishing its role 
as a neurotransmitter.
The serotonin molecule has some remarkable properties. 
It is synthesized by two different genes at two different 
sites,  and,  surprisingly,  plays  antagonistic  functions  on 
bone mass accrual at these two sites. When produced   
peripherally, serotonin acts as a hormone to inhibit bone 
formation. In contrast, when produced in the brain, sero-
tonin acts as a neurotransmitter to exert a positive and 
dominant effect on bone mass accrual by enhancing bone 
formation and limiting bone resorption. The effect of sero-
tonin on bone biology could be harnessed pharmacologi-
cally to treat diseases such as osteoporosis.
The two faces of serotonin in bone biology
Patricia Ducy
1 and Gerard Karsenty
2
1Department of Pathology and Cell Biology and 
2Department of Genetics and Development, Columbia University Medical Center, New York, NY 10032
© 2010 Ducy and Karsenty  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the pub-
lication date (see http://www.rupress.org/terms). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, 
as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
YJCB • VOLUME 191 • NUMBER 1 • 2010   
visible distress and cannot be revealed by a mere physical ex-
amination. To be detected, those abnormalities require specific 
techniques performed only in bone biology laboratories. Hence, 
none of the initial studies of the Tph1-deficient mice identified 
the potent action that gut-derived serotonin has on the skeleton. 
This needs to be underscored because it was only later, and by 
serendipity, that the paramount importance of gut-derived sero-
tonin in bone biology was identified.
Lrp5 is an atypical member of the low-density lipoprotein 
receptor family of cell surface proteins (Bhanot et al., 1996). Its 
function in bone biology was brought to light in 2001 by two 
human genetic studies. Gain-of-function mutations in Lrp5 were 
shown to cause the high bone mass syndrome (HBM), a high 
bone mass phenotype appearing only in adolescents and persist-
ing into adulthood. Loss-of-function mutations in Lrp5 cause 
osteoporosis pseudoglioma (OPPG), a disease associated with 
blindness at birth and bone loss appearing in the first 2 yr of life 
(Gong et al., 2001; Boyden et al., 2002). By identifying Lrp5 as 
a major regulator of postnatal bone formation in humans, these 
findings immediately raised the prospect that manipulating its 
expression, function, or signaling pathway could have a major 
therapeutic impact. Three other aspects further reinforced this 
notion. First, in either Lrp5 gain- or loss-of-function models, 
only the bone formation arm of bone remodeling is affected, 
which indicates that enhancing Lrp5 signaling would provide 
an anabolic therapy (Gong et al., 2001; Boyden et al., 2002; 
Kato et al., 2002). Second, in contrast to mutations in Sclerostin 
(SOST), whose absence in Van Buchem patients (or mice) cause 
high bone mass but also skeleton overgrowth, hearing loss, and 
hyperostosis (Brunkow et al., 2001; van Bezooijen et al., 2005; 
Li et al., 2008), HBM patients do not develop overt deleteri-
ous phenotypes; an observation that implies that targeting Lrp5 
could be safe. Lastly, the phenotype caused by Lrp5 deficiency 
was identical in mice and in humans, which indicates that using 
the mouse as a model was a convenient and yet reliable mean to 
study Lrp5 biology (Kato et al., 2002). Facing these human and 
mouse observations, bone biologists launched an extraordinary 
large effort to identify the molecular bases of Lrp5 action on 
bone formation.
Lrp5 and its closest relative Lrp6 are vertebrate homo-
logues of the Drosophila gene arrow, a coreceptor for Wingless 
and an enhancer of Wnt signaling (Bhanot et al., 1996). Like 
Lrp6, Lrp5 can enhance Wnt canonical signaling in cultured 
cells, and the blindness observed in OPPG patients and Lrp5-
deficient mice is caused by the dysregulation of Wnt canonical 
signaling during eye development (Tamai et al., 2000; Boyden 
et al., 2002; Kato et al., 2002; Lobov et al., 2005). This bio-
chemical and genetic evidence only reinforced the dogma that   
it was also in this capacity that LRP5 was acting on osteoblasts 
(Tamai et al., 2000). Yet, clinical and experimental evidence 
contradicted this dogma.
First,  there  is  no  detectable  bone  abnormality  at  birth 
in Lrp5
/ mice or in OPPG and HBM patients (Gong et al., 
2001; Boyden et al., 2002; Kato et al., 2002); in the context   
of a Wnt-dependent mechanism, this is surprising because all 
Wnt proteins identified and studied so far have a function during 
development (Parr and McMahon, 1994; Freese et al., 2010).   
It is also during this early period of the history of sero-
tonin that the first hint of a dissociation between circulating and 
central serotonin surfaced. This followed the observation that 
patients with carcinoïd syndrome, a combination of symptoms 
and lesions caused by the release of serotonin from carcinoid 
tumors of the gastrointestinal tract that have metastasized to the 
liver, have a massive elevation of circulating serotonin. Yet these 
patients do not develop cognitive disorders or migraines, two 
clinical manifestations associated with excess serotonin activity 
(Sjoerdsma, 1959; Sjoerdsma and Palfreyman, 1990). This dis-
sociation is explained by the fact that serotonin cannot cross the 
blood–brain barrier; hence, altering its levels peripherally does 
not influence its central concentration, or vice versa (Mann et al., 
1992). In other words, serotonin central and peripheral functions 
may be completely dissociated.
Serotonin is synthesized in a two-step process whereby 
l-tryptophan is first hydroxylated in a rate-limiting fashion into 
l-5-hydroxytryptophan by a specific tryptophan hydroxylase   
(Tph) and then decarboxylated by an l–amino acid decar-
boxylase (Grahame-Smith, 1964; Lovenberg et al., 1967). Until   
<10 yr ago, it was assumed that there was only one Tph enzyme, 
encoded by the Tph1 gene. With the normal levels of brain   
serotonin and the absence of neurological disorder observed 
in Tph1-deficient mice came the realization that another gene, 
most likely brain-specific, must be responsible for the synthesis 
of serotonin in the central nervous system (Walther and Bader, 
2003; Walther et al., 2003). That serotonin is synthesized by 
two distinct genes centrally and peripherally and that it does not 
cross the blood–brain barrier created the opportunity to study 
separately the role of each pool of serotonin using mouse ge-
netic experiments. This approach was highly successful in the 
case of bone biology, as it showed that both brain and gut sero-
tonin regulate bone mass accrual but do it in opposite fashions 
and through different pathways.
Gut-derived serotonin: a long, winding road 
to a function
As mentioned earlier, the major peripheral site of serotonin pro-
duction is the gastrointestinal tract (Gershon and Tack, 2007). 
Based on this pattern of expression and clinical observations 
associating high or low levels of blood serotonin with bowel 
disorders, it was expected that the serotonin produced in the 
gut was essential to regulate its movement. Likewise, because 
platelets contain most (>95%) of the serotonin present in the 
general circulation, and serotonin is released upon platelet   
aggregation, it was logically assumed that inactivating Tph1 
function would lead to severe blood clotting defects (Holland, 
1976; Gershon and Tack, 2007). Yet, mice deficient in Tph1 do not 
display an obvious phenotype in either of these two functions: they 
are born alive, have a normal life span, and show only minor 
abnormalities at the digestive or coagulation levels (Walther   
et al., 2003). Thus, for a long time the only impact of the Tph1-
deficient mice on the field of serotonin had been to allow the 
identification of another gene, Tph2, involved in the synthesis 
of serotonin in the brain.
Like its main disorder, osteoporosis, most abnormalities 
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be a therapeutic approach to this disease (Yadav et al., 2008; 
Yadav and Ducy, 2010).
Osteoporosis is the most frequent degenerative disease in 
the Western hemisphere. This prevalence and the progressive 
increase of life expectancy in this part of the world explain why 
its prevention and treatment are major public health issues in 
developed countries. The bone loss and risk of fracture character-
izing osteoporosis result from an increase in bone resorption, 
caused by gonadal failure or aging, that is not compensated by 
a similar increase in bone formation (Rodan and Martin, 2000). 
At the present time, most therapeutic strategies target bone re-
sorption, slowing down the process of bone loss but not fully 
restoring bone mass (Russell, 2007; Bilezikian, 2009). The only 
available anabolic therapy is PTH, but this treatment is inject-
able, costly, approved selectively for high-risk patients and only 
for 2 yr (Ebeling and Russell, 2003; Vegni et al., 2004; Hodsman 
et al., 2005). There is therefore a need to define novel anabolic 
strategies. In that context, decreasing serotonin synthesis in the 
gut pharmacologically becomes an attractive prospect.
Indeed, when rodents are treated orally with an inhibitor 
of Tph1 that does not cross the blood–brain barrier, and there-
fore does not affect Tph2, a high bone mass phenotype reminis-
cent of the one observed in absence of Tph1 or in HBM patients 
is observed (Yadav et al., 2010b). More importantly, this inhibi-
tor can prevent bone loss, and even treat an established osteo-
porosis, in ovariectomized mice and rats through an isolated 
increase in bone formation. As a result, bone mass and bone 
strength are preserved to the same extent as in rodents treated 
with high daily doses of PTH (Yadav et al., 2010b). Remark-
ably, these effects can be achieved through a moderate decrease 
in serum serotonin (<50%) and thereby do not cause any hemo-
stasis or bowel movement disorders (Yadav et al., 2010b).   
Although clinical data using this strategy are not available yet, 
As a matter of fact, the Wnt-dependent function that Lrp5 plays 
in the eyes is developmental, and this is why the blindness of 
OPPG patients is perinatal (Lobov et al., 2005). Second, HBM 
patients  with  gain-of-function  mutations  in  LRP5  never  de-
velop tumors, yet this is a hallmark of increased Wnt signal-
ing in most other organs (Moon et al., 2004; Clevers, 2006). 
Third, and more directly, inactivation of canonical Wnt signal-
ing in osteoblasts or even osteocytes does not impair postnatal 
bone formation, as Lrp5 inactivation does, but instead enhances   
osteoblast-directed bone resorption (Glass et al., 2005; Kramer 
et al., 2010). Consistent with these data, inactivation of Lrp5 and 
activation of -catenin, the molecular node of Wnt canonical 
signaling, affect different transcriptomes in osteoblasts (Glass 
et al., 2005; Yadav et al., 2008). Lastly, inactivation of Lrp5 in 
osteoblasts progenitors does not affect bone formation (or bone 
homeostasis), whereas inactivation of canonical Wnt signaling 
does (Day et al., 2005; Hill et al., 2005; Yadav et al., 2010a). 
Taken at face value, these observations suggested that Lrp5 and 
canonical Wnt signaling use different mechanisms to regulate 
osteoblast function (Fig. 1).
At that point, the notion that Lrp5 is not an osteoblast-specific 
gene became important (Kato et al., 2002). Indeed, analysis of 
a microarray experiment comparing bones from Lrp5
/ and 
wild-type littermate mice provided the totally unexpected clue 
that the gene most highly overexpressed in Lrp5-deficient bones 
was Tph1 (Yadav et al., 2008). Further analyses confirmed that 
Tph1 expression in the gut is increased in the absence of Lpr5, 
as are serum serotonin levels in Lrp5-deficient patients or mice 
(Yadav et al., 2008; Saarinen et al., 2010; Yadav et al., 2010a). 
Even more suggestive was the fact that consistent with the ab-
sence of bone phenotype at birth in Lrp5
/ mice and OPPG 
patients, these changes in serotonin production only occur post-
natally (Kato et al., 2002; Yadav et al., 2008).
Pharmacologic, genetic, expression, and cell culture stud-
ies subsequently confirmed that Tph1 and gut-derived serotonin 
synthesis were (a) regulatory targets of Lrp5 and (b) potent 
regulators of bone formation (Fig. 2). First, feeding Lrp5
/ 
mice with a low-tryptophan diet that decreased serotonin lev-
els in serum without affecting brain serotonin content normal-
ized their bone mass and bone formation parameters (Yadav   
et al., 2008). Second, treatment of Lrp5
/ mice with parachloro-
phenylalanine (pCPA), a drug inhibiting serotonin synthesis, 
also rescued their bone phenotype (Yadav et al., 2008). Consis-
tent with the fact that their eye phenotype is caused by failure 
of a Wnt-dependent process, this phenotype was not rescued in 
pCPA-treated Lrp5-deficient mice (Lobov et al., 2005; Yadav 
et al., 2008). The bone phenotype of the Lrp5-deficient mice 
could also be rescued by deleting one allele of Tph1 specifically 
in gut cells (Yadav et al., 2008). On its own, gut-specific Tph1 
inactivation but also Tph1 haploinsufficiency led to a high bone 
mass phenotype, mirroring at the cellular and molecular lev-
els Lrp5 deficiency; i.e., a major increase in osteoblast number 
and bone formation without consequences on bone resorption 
(Kato et al., 2002; Yadav et al., 2008). That this anabolic effect 
was sufficient to prevent bone loss in Tph1-deficient mice upon 
ovariectomy, a model of postmenopausal osteoporosis, raised 
the prospect that targeting serotonin synthesis in the gut could 
Figure  1.  The  contrasting  roles  of  Wnt  and  Lrp5  signaling  in  bone   
remodeling. (A) Binding of Wnt to Frizzled (Fz) receptors expressed by 
osteoblasts causes intracellular -catenin stabilization. In cooperation with 
LEF/TCF  transcription  factors,  -catenin  then  activates  transcription  of   
osteoprotegerin (OPG), a cytokine secreted by osteoblasts that decreases 
bone resorption. (B) Lrp5 signals in an unknown cell type, through an   
unknown mechanism, to increase of bone formation by osteoblasts.JCB • VOLUME 191 • NUMBER 1 • 2010   10
results from an effect on both arms of bone remodeling: it is 
secondary to a decrease in bone formation parameters as well 
as to an increase in bone resorption parameters (Yadav et al., 
2009). Further analysis of the molecular basis of this pheno-
type revealed that both these effects are mediated by an increase 
in sympathetic tone (Yadav et al., 2009). Hence, brain-derived   
serotonin appeared to be a positive and powerful regulator of 
bone mass accrual acting on both arms of bone remodeling via 
the sympathetic tone as well as a molecule regulating food intake 
and energy expenditure (Yadav et al., 2009). This combination 
of phenotypes was reminiscent, although exactly opposite, of 
another mutant model: the ob/ob mice.
ob/ob mice are a natural mutant strain deficient in leptin, a 
vertebrate-specific  adipocyte-derived  hormone  regulating  bone 
mass, appetite, and energy expenditure among other physiological 
processes (Zhang et al., 1994; Friedman and Halaas, 1998; Ducy 
et al., 2000; Takeda et al., 2002; Karsenty, 2006). To fulfill these 
functions, leptin uses a central relay that requires the integrity of 
the arcuate (ARC) and ventromedial hypothalamic (VMH) nuclei 
(Hetherington, 1940; Takeda et al., 2002). Yet, leptin does not need 
to signal directly to these nuclei, as inactivation of its sole signaling 
receptor, ObRb, specifically in either of these nuclei does not repro-
duce the high bone mass, increased appetite, or decreased energy 
expenditure observed in the ob/ob mice or in global ObRb-deficient 
mice (db/db mice) fed a normal diet (Friedman and Halaas, 1998; 
Balthasar et al., 2004; Dhillon et al., 2006; Karsenty, 2006).
In contrast, several correlative evidences are consistent 
with the notion that serotonin could mediate some of leptin’s 
central functions. First, ObRb is expressed on the same brainstem 
neurons of the raphe nuclei that produce serotonin (Hay-Schmidt 
et al., 2001; Scott et al., 2009; Yadav et al., 2009). Second, when 
injected in the lateral cerebral ventricle, leptin localizes to sero-
tonergic neurons of the raphe nuclei, which suggests that these 
cells may respond to leptin (Michelson et al., 1999; Fernández-
Galaz et al., 2002). Third, leptin administration modifies sero-
tonin turnover and transport in different regions of the brain, 
and in particular it inhibits serotonin release from brainstem 
neurons where it is synthesized (Calapai et al., 1999; Charnay 
et al., 2000; Yadav et al., 2009). More direct evidence emerged 
from the inactivation of the leptin receptor in serotonergic neu-
rons of the brainstem. For instance, and in contrast to mice 
lacking ObRb in either VMH or ARC, mice lacking the leptin 
receptor in serotonergic neurons developed a high bone mass 
phenotype, displayed increased appetite, low energy expendi-
ture, and obesity, as ob/ob mice do (Yadav et al., 2009). Con-
firming these genetic data, intracerebroventricular injection of 
leptin decreases the synthesis as well as the release of serotonin 
by brainstem neurons in wild-type mice; ob/ob mice have high 
contents of serotonin in the hypothalamus, and normalizing this 
content normalizes their bone, appetite, and energy expenditure 
phenotype (Yadav et al., 2009). How do these results fit with the 
requirement of the VHM and ARC nuclei in mediating leptin 
functions? Axon guidance experiments answered this question 
by showing that brainstem serotonergic neurons connect to both 
ARC and VMH neurons (Yadav et al., 2009).
Altogether,  these,  neuroanatomical,  cellular,  and  genetic 
studies concur to demonstrate that brain serotonin regulates bone 
one piece of evidence already exists showing that this therapeutic 
approach could also be relevant to human biology. As mentioned 
earlier, the identification of Lrp5 as a positive determinant of bone 
formation came in part from the study of patients affected by HBM. 
Two studies have now shown that HBM patients have signifi-
cantly decreased serotonin levels (Yadav et al., 2008; Frost et al., 
2010). These observations not only support the notion that cir-
culating serotonin is a negative regulator of bone mass in humans 
but also suggest that decreasing the synthesis of serotonin in gut 
in humans could be a viable approach to treat osteoporosis.
Regulation of both arms of bone remodeling 
by brain-derived serotonin
The realization that gut-derived serotonin regulates bone forma-
tion immediately raised the question of whether brain-derived 
serotonin also influences bone mass. Because serotonin does not 
cross the blood–brain barrier, a positive answer to this question 
would provide the first evidence that a true neurotransmitter   
has a physiological effect on bone mass. Indeed, in addition to 
expected behavior and mood abnormalities, Tph2-deficient 
mice demonstrate a bone loss phenotype; they are also anorectic 
and have increased energy expenditure (Yadav et al., 2009), two 
features that helped to integrate serotonin within a broader physio-
logical context (see below).
In contrast with the Tph1-deficient phenotype, the severe 
low bone mass phenotype observed in the absence of Tph2 
Figure 2.  Opposite regulation of bone mass accrual by gut- and brain-
derived serotonin. The synthesis of gut-derived serotonin by enterochro-
maffin cells is controlled by the negative regulation that Lrp5 exerts on 
the expression of Tph1 in these cells. When gut serotonin is released in 
blood, its free circulating form negatively regulates the bone formation arm 
of bone remodeling. In the brain, the synthesis of serotonin by brainstem 
neurons, which express the leptin receptor (ObRb), is negatively controlled 
by leptin through its effect on Tph2 expression in these cells. Brain-derived 
serotonin acts, via an indirect mechanism, on both arms of bone remodel-
ing to increase bone formation and decrease bone resorption. The periph-
eral and central actions of serotonin on bone are independent of each 
other because serotonin does not cross the blood–brain barrier. Question 
marks indicate mechanisms not yet defined. Solid lines, direct actions;   
broken lines, indirect mechanisms.11 Dual roles of serotonin in bone biology • Ducy and Karsenty
main mediator of the leptin-dependent central regulation of bone 
mass (Takeda et al., 2002; Karsenty, 2006) suggest a model 
whereby serotonin via Htr2c and the sympathetic tone regulates 
both the bone formation and osteoclast activation functions of the 
osteoblast (Fig. 3).
Of note, two other receptors, Htr1a and Htr2b, turned out to 
mediate the leptin/serotonin-dependent regulation of appetite 
and energy expenditure through their expression in neurons of 
the ARC hypothalamic nuclei (Yadav et al., 2009).
Conclusion and future directions
Understanding  the  mechanism  of  serotonin  action  on  bone   
biology has been facilitated, in fact has been made possible, by 
mass, appetite, and energy expenditure, and that this regulation   
is under the negative control of Tph2 expression in brainstem 
neurons by leptin (Fig. 2).
Signaling of serotonin to bone:  
two serotonins, two pathways
The wide diversity of serotonin actions is attributed to its ability 
to signal through as many as 14 different receptors (Saudou and 
Hen, 1994; Heath and Hen, 1995; Berger et al., 2009). For its 
regulation of bone mass, serotonin essentially uses two of them: 
Htr1b and Htr2c.
Three serotonin receptors, Htr1b, Htr2a, and Htr2b, are ex-
pressed in osteoblasts (Yadav et al., 2008). A global inactivation 
of Htr2b results in a decreased bone density in female mice aged 
4 mo or older because of reduced bone formation (Collet et al., 
2008). This phenotype, which appears later than the one observed 
in Tph1-deficient mice, is not consistent with the inhibitory role of 
serotonin on osteoblast proliferation in vitro or in vivo (Yadav et al.,   
2008). Moreover, an osteoblast-specific deletion of Htr2b does 
not affect bone mass at 1 or 3 mo of age, two time points at which 
Lrp5-deficient and Tph1-deficient mice already display severe bone 
loss (Yadav et al., 2008). In contrast, either global or osteoblast- 
specific deletion of Htr1b causes a high bone mass phenotype,   
mirroring the cell and molecular bases caused by the lack of Tph1 
(Yadav et al., 2008). In osteoblasts, binding of serotonin to Htr1b 
inhibited cAMP production and PKA-mediated cAMP response 
element-binding (CREB) phosphorylation (Yadav et al., 2008). 
Consistent with this result, osteoblast-specific inactivation of 
Creb leads to a low bone mass, low bone formation phenotype, 
and decreasing CREB levels in Htr1b-deficient mice normalizes 
their high bone mass phenotype (Yadav et al., 2008). Additional   
in vitro and in vivo gene expression analyses in Lrp5-deficient, 
Tph1-deficient, and Htr1b-deficient mice identified the Cyclin D1, 
D2, and E1 genes as transcriptional targets of CREB under the 
control of gut serotonin (Yadav et al., 2008). These observations 
therefore indicate that osteoblasts are direct targets of gut-derived 
serotonin and that an Htr1b/PKA/CREB/cyclins signaling cascade 
is mediating its regulation of the proliferation of these cells (Fig. 3).
The molecular mechanism whereby brain serotonin favors 
bone mass accrual is less well understood. Double fluorescence   
in situ hybridization demonstrated that Htr2c receptors are ex-
pressed on VMH nuclei (Yadav et al., 2009). VMH-specific gene 
inactivation experiments in mice demonstrated that the absence of 
Htr2c receptors in these neurons results in a severe low bone mass 
caused by a decrease in bone formation and an increase in bone 
resorption associated with increased sympathetic activity, as is the 
case in the absence of Tph2 (Yadav et al., 2009). That Htr2c and   
serotonin are in the same genetic cascade controlling bone mass   
was confirmed when compound mutant mice lacking one allele   
of Tph2 and one allele of Htr2c (Tph2
+/;Htr2c
+/ mice) were 
shown to display the same low bone mass/high sympathetic activ-
ity phenotype as Htr2c
/ and Tph2
/ mice (Yadav et al., 2009). 
Brain serotonin therefore acts on VMH neurons, through Htr2c, 
to decrease sympathetic activity and to favor bone mass accrual. 
The fact that serotonin is known to attenuate activation of nor-
adrenergic neurons in the locus coeruleus of the brainstem (Aston-
Jones et al., 1991) and that the sympathetic nervous system is the   
Figure 3.  The different effects of gut- and brain-derived serotonin on the 
osteoblast. The free circulating form of gut-derived serotonin directly sig-
nals to the osteoblast by binding to the Htr1b receptor. This binding inhibits 
the phosphorylation of CREB by PKA, leading to decreased expression of 
Cyclin (Cyc) genes and decreased osteoblast proliferation. As a result, 
bone formation is slowed down. In contrast, serotonergic neurons of the 
dorsal raphe (DR) signal to VMH neurons via the Htr2c receptor to inhibit 
the synthesis of epinephrine and thereby decrease sympathetic tone. This 
decrease is relayed in osteoblasts by decreased signaling via the 2 ad-
renergic receptor (Adr2), which negatively controls osteoblast prolifera-
tion via a molecular clock gene/cyclinD1 (Cyc D1) cascade and positively 
regulates bone resorption via activation of a PKA/ATF4-dependent path-
way, leading to increased synthesis of Rankl, an activator of osteoclast 
differentiation and function. The inhibition of sympathetic activity by brain-
derived serotonin thus results in increased formation and decreased resorp-
tion. Solid lines, direct actions; broken lines, indirect mechanisms.JCB • VOLUME 191 • NUMBER 1 • 2010   12
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the ability to make cell-specific gene deletions. Indeed, whole 
animal deletions of Tph1 or serotonin receptors cause a range 
of complex, sometimes even opposite, manifestations that mask 
the effect of serotonin on bone. Thus, technological advances have 
been instrumental in elucidating serotonin function.
Studying the regulation of bone remodeling by serotonin 
has brought to light the pleiotropic nature of this molecule. Indeed, 
it provides a unique example of a molecule fulfilling opposite 
functions on the same physiological process, via totally differ-
ent signaling modes, depending on its site of synthesis and by 
acting on different cells, neurons or osteoblasts. It has also pro-
vided an answer for the long-standing question regarding leptin 
signaling in the brain. Just as importantly, these studies have put 
a new emphasis on the importance of gut-derived serotonin and 
placed it at the center of potentially new therapeutic strategies 
to treat bone disorders as common as osteoporosis. Doing so, 
they have also brought to light that a disease proper to one organ 
can be treated from a distance by targeting another organ. All 
in all these studies have also considerably enriched our under-
standing of the biology of bone.
This does not mean that we have all the answers. Indeed,   
we do not know what extracellular signals regulate the Lrp5/ 
serotonin cascade in gut cells or how Lrp5 regulates Tph1 expres-
sion (Fig. 2). Likewise, the transcriptional bases of the regulation 
of Tph2 expression in brainstem neurons by the leptin receptor 
and the molecular pathway downstream of serotonin signaling 
in VMH neurons remain to be identified (Fig. 2). Last but not 
least, it remains to be determined whether decreasing peripheral 
serotonin levels can become a treatment for osteoporosis.
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